SEC 13F Intelligence

Natixis Advisors, LLC / VRTX

Natixis Advisors, LLC’s Vertex Pharmaceuticals Inc Position

Does Natixis Advisors, LLC own Vertex Pharmaceuticals Inc (VRTX)? Yes — 554.0K shares worth $247M (+0.34% of its 13F portfolio) as of Q1 2026, up from 527.9K shares the prior filed quarter.

Position Value
$247M
Q1 2026
Shares
554.0K
% of Portfolio
+0.34%
Quarters Held
30
currently held

Position History VRTX

Reported value by quarter
Q4 ’18: $21MQ4 ’18Q1 ’19: $22MQ2 ’19: $24MQ3 ’19: $23MQ4 ’19: $31MQ4 ’19Q1 ’20: $37MQ2 ’20: $57MQ3 ’20: $57MQ4 ’20: $33MQ4 ’20Q1 ’21: $37MQ2 ’21: $42MQ3 ’21: $112MQ4 ’21: $147MQ4 ’21Q1 ’22: $175MQ2 ’22: $170MQ3 ’22: $147MQ4 ’22: $135MQ4 ’22Q1 ’23: $146MQ2 ’23: $167MQ3 ’23: $111MQ4 ’23: $130MQ4 ’23Q1 ’24: $139MQ2 ’24: $205MQ3 ’24: $215MQ4 ’24: $225MQ4 ’24Q1 ’25: $291MQ2 ’25: $241MQ3 ’25: $210MQ4 ’25: $239MQ4 ’25Q1 ’26: $247Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026554.0K$247M+0.34%
Q4 2025527.9K$239M+0.34%
Q3 2025537.2K$210M+0.31%
Q2 2025540.5K$241M+0.38%
Q1 2025601.2K$291M+0.54%
Q4 2024557.6K$225M+0.42%
Q3 2024461.9K$215M+0.42%
Q2 2024436.6K$205M+0.44%
Q1 2024332.1K$139M+0.32%
Q4 2023319.5K$130M+0.34%
Q3 2023319.2K$111M+0.34%
Q2 2023473.2K$167M+0.51%
Q1 2023463.0K$146M+0.50%
Q4 2022467.3K$135M+0.51%
Q3 2022508.4K$147M+0.62%
Q2 2022604.2K$170M+0.75%
Q1 2022670.5K$175M+0.67%
Q4 2021667.8K$147M+0.56%
Q3 2021616.7K$112M+0.46%
Q2 2021208.8K$42M+0.20%
Q1 2021171.1K$37M+0.19%
Q4 2020140.5K$33M+0.19%
Q3 2020210.0K$57M+0.36%
Q2 2020197.0K$57M+0.38%
Q1 2020156.2K$37M+0.30%
Q4 2019139.3K$31M+0.22%
Q3 2019138.3K$23M+0.19%
Q2 2019129.6K$24M+0.19%
Q1 2019121.0K$22M+0.19%
Q4 2018129.2K$21M+0.21%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Natixis Advisors, LLC’s full portfolio or all institutional holders of VRTX.